JP2022140191A - Therapeutic agent for hepatitis - Google Patents
Therapeutic agent for hepatitis Download PDFInfo
- Publication number
- JP2022140191A JP2022140191A JP2021076788A JP2021076788A JP2022140191A JP 2022140191 A JP2022140191 A JP 2022140191A JP 2021076788 A JP2021076788 A JP 2021076788A JP 2021076788 A JP2021076788 A JP 2021076788A JP 2022140191 A JP2022140191 A JP 2022140191A
- Authority
- JP
- Japan
- Prior art keywords
- hepatitis
- therapeutic agent
- rna
- dna
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
本発明は、肝炎治療薬に関する。The present invention relates to a therapeutic agent for hepatitis.
肝炎を根本的に治療する薬がない。There is no drug that can cure hepatitis.
肝炎治療薬を提供することを目的とする。The purpose is to provide a therapeutic drug for hepatitis.
本発明の目的を達成するため、次の構成を採用する。
肝炎ウイルスに感染し、肝臓の細胞が少しずつ壊れていく病気をウイルス性肝炎と呼ぶ。肝臓はその半分を失っても命に影響がない予備力がある丈夫な臓器だが、この病気を患うと徐々に肝臓の機能が失われてゆき、ついには肝硬変や肝臓がんなどの死に直結する疾患にまで進行していく。主な肝炎ウイルスにはＡ型、Ｂ型、Ｃ型、Ｄ型、Ｅ型の５種類があり、これらが引き起こす肝炎の種類には慢性肝炎と急性肝炎がある。慢性肝炎はＢ、Ｃ型によるものが多く、長期にわたり軽度の肝障害が続く。Ｄ型肝炎はＢ型肝炎ウイルスと重複して慢性肝炎を引き起こす。急性肝炎はＡ、Ｂ、Ｅ型によるものが多く発熱や全身倦怠感、黄疸などの症状があるが、自然治癒の可能性が高い。急性肝炎が著しく重症化すると劇症肝炎と呼ばれ、その致死率は７０％と非常に高い。
肝炎ウイルスは、血液や体液を介して人から人へと感染するものと、不衛生な水を含めた飲食で感染するものがある。
肝炎の原因である肝炎ウイルスを壊滅するため、変性剤を人体に投入することにより、身体に侵入した肝炎ウイルスのＤＮＡとＲＮＡを壊すことにより肝炎ウイルスの増殖を防ぎ、肝炎の治療をする。
肝炎ウイルスという肝炎の病原体は、核酸を持っている。
核酸とは、ＤＮＡとＲＮＡのことである。
ＤＮＡとＲＮＡは塩基間で水素結合しているが、変性剤を加えてアルカリ性にすると、水素イオンを放出するため変性し、ＤＮＡとＲＮＡの水素結合が壊れる。
変性剤を加えてＤＮＡとＲＮＡを壊すことにより、肝炎ウイルスの増殖を防ぐことができるため、変性剤という肝炎治療薬となる。In order to achieve the objects of the present invention, the following configuration is adopted.
Viral hepatitis is a disease in which liver cells are gradually destroyed by hepatitis virus infection. The liver is a strong organ with reserve power that does not affect life even if half of it is lost. progress to disease. There are five main types of hepatitis viruses, namely type A, type B, type C, type D, and type E, and types of hepatitis caused by these viruses include chronic hepatitis and acute hepatitis. Chronic hepatitis is often caused by type B or C, and mild liver damage continues for a long period of time. Hepatitis D overlaps with hepatitis B virus to cause chronic hepatitis. Acute hepatitis is often caused by types A, B, and E, and symptoms such as fever, general malaise, and jaundice occur, but there is a high possibility of spontaneous recovery. When acute hepatitis becomes extremely severe, it is called fulminant hepatitis, and its fatality rate is as high as 70%.
Hepatitis viruses are transmitted from person to person through blood or bodily fluids, and are transmitted through eating and drinking including unsanitary water.
In order to destroy the hepatitis virus which is the cause of hepatitis, a denaturing agent is put into the human body to destroy the DNA and RNA of the hepatitis virus that has invaded the body, thereby preventing the proliferation of the hepatitis virus and treating the hepatitis.
Hepatitis virus, the pathogen of hepatitis, has nucleic acid.
Nucleic acids refer to DNA and RNA.
Although DNA and RNA are hydrogen-bonded between bases, when a denaturing agent is added to make them alkaline, hydrogen ions are released and they are denatured, breaking the hydrogen bond between DNA and RNA.
By adding a denaturing agent to destroy DNA and RNA, it is possible to prevent the proliferation of the hepatitis virus, so it becomes a hepatitis therapeutic agent called a denaturing agent.
変性剤という肝炎の治療薬を人体に投与することにより、肝炎を治療する。
代表的な変性剤は、尿素薬がある。Hepatitis is treated by administering a therapeutic drug for hepatitis called a denaturant to the human body.
A representative denaturant is a urea drug.
変性剤という肝炎の治療薬を飲み薬として飲むか、注射により投与する。
肝臓の部分を標的とする変性剤を有効成分とするリポソーム医薬品として、人体に投与する方法もある。
代表的な変性剤は、尿素薬がある。Hepatitis treatment drugs called denaturing agents are taken by mouth or given by injection.
There is also a method of administering to the human body as a liposome drug containing as an active ingredient a denaturing agent that targets the liver part.
A representative denaturant is a urea drug.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021076788A JP2022140191A (en) | 2021-03-12 | 2021-03-12 | Therapeutic agent for hepatitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021076788A JP2022140191A (en) | 2021-03-12 | 2021-03-12 | Therapeutic agent for hepatitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2022140191A true JP2022140191A (en) | 2022-09-26 |
Family
ID=83398952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021076788A Pending JP2022140191A (en) | 2021-03-12 | 2021-03-12 | Therapeutic agent for hepatitis |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2022140191A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010513508A (en) * | 2006-12-18 | 2010-04-30 | アキリオン ファーマシューティカルズ，インコーポレーテッド | Combination therapy to treat hepatitis C infection |
-
2021
- 2021-03-12 JP JP2021076788A patent/JP2022140191A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010513508A (en) * | 2006-12-18 | 2010-04-30 | アキリオン ファーマシューティカルズ，インコーポレーテッド | Combination therapy to treat hepatitis C infection |
Non-Patent Citations (3)
| Title |
|---|
| BIOCHEMISTRY, vol. 2, no. 1, JPN6021028387, 1963, pages 168 - 175, ISSN: 0004828115 * |
| 福井県衛生環境研究センター年報, vol. 13, JPN6021028388, 2014, pages 99 - 101, ISSN: 0004828117 * |
| 薬学雑誌, vol. 87, no. 8, JPN6021028389, 1967, pages 1006 - 1009, ISSN: 0004828116 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PA8744101A1 (en) | METHOD OF COMBINED THERAPY FOR THE TREATMENT OF INFECTION BY THE VIRUS OF HEPATITIS C AND PHARMACEUTICAL COMPOSITIONS FOR USE IN SUCH THERAPY | |
| JP2006306892A (en) | Method for pasteurization of blood-plasma | |
| JP2022140191A (en) | Therapeutic agent for hepatitis | |
| JPH0378850B2 (en) | ||
| JP4351663B2 (en) | Use of alpha-1 antitrypsin for the preparation of a medicament for the treatment of fibromyopathy | |
| JP2022140193A (en) | Therapeutic agent for rheumatic diseases | |
| JP2022151431A (en) | Agent for treating enteritis | |
| JP2022151432A (en) | Agents for treating myocarditis and pericarditis | |
| JP2022151439A (en) | Agents for treating rhinitis | |
| JP2022151436A (en) | Agents for treating meningitidis and encephalitis | |
| JP2022151429A (en) | Agents for treating pancreatitis | |
| Mizera et al. | ROS scavenger decreases basal perfusion pressure, vasoconstriction and NO synthase activity in pulmonary circulation during pulmonary microembolism | |
| JP2022151437A (en) | Agents for treating retinitis | |
| JP2022146830A (en) | Therapeutic agent for retinal detachment | |
| JP2022151430A (en) | Agents for treating cholecystitis | |
| JP2022151440A (en) | Agents for treating arthritis | |
| JP2022151428A (en) | Agent for treating nephritis | |
| JP2022151427A (en) | Agents for treating esophagitis | |
| JP2022151433A (en) | Agents for treating cystitis | |
| WO2022019742A1 (en) | Pharmaceutical package for preventing and/or treating covid-19 disease and use of same | |
| JP2022140192A (en) | Therapeutic agent for bronchitis | |
| JP2022140190A (en) | Therapeutic agent for autoimmune diseases | |
| JP2022124985A (en) | Pneumonia therapeutic drugs | |
| JP2022151438A (en) | Agents for treating conchitis and tympanitis | |
| JP2022140194A (en) | Therapeutic agent for connective tissue diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20210324 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210817 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220719 |